Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma

Kelsen, David P.; Hilaris, Basil S.; Coonley, Craig J.; Chapman, Robert A.; Lesser, Martin; Dukeman, M; Heelan, Robert T.; Bains, Manjit S.

doi:10.1016/0002-9343(83)90451-5

Cited by 119 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The postoperative complication rate was also not increased. Therefore, chemotherapy according to this protocol seems to be safe and dose not increase the drug-related mortality, as previous studies have shown [10][11][12][13][14][15][16][17][18][19][20]. A response in the IMM was seen in 66.7% of patients, that was the same as that in the primary lesion as reported by various studies [10][11][12][13][14][15][16][17][18][19][20].…”

Section: Discussionsupporting

confidence: 72%

Preoperative chemotherapy for esophageal carcinoma with intramural metastasis

et al. 2000

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Preoperative chemotherapy for esophageal carcinoma with intramural metastasis

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Our experience supports the earlier reports of Kelsen et a1., 2 Leichman and associate^,^ Miller and colleagues,* and DeBesten' indicating that multimodality therapy utilizing chemotherapy in the initial phase of treatment is both feasible and effective. Preoperative chemotherapy induces tumor regression in a substantial percentage of cases and may have additional effects on microscopic nodal or distant metastases that only further follow-up will clarify.…”

Section: Discussionmentioning

confidence: 99%

Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer

Kies

Rosen

Tsang

et al. 1987

Cancer

View full text Add to dashboard Cite

A combined treatment program consisting of chemotherapy with cisplatin and infusion 5-fluorouracil (5-FU) for three cycles followed by esophagectomy or radiation, or both, has been conducted in 26 patients with squamous cancer of the esophagus localized to the primary site. Eleven patients had objective evidence of partial or complete response to the chemotherapy. Fourteen patients were operated on and ten underwent total esophagectomy. Drug toxicity was considerable with severe mucositis and myelosuppression occurring in 11 and seven patients, respectively. There were no drug-related deaths. Median survival is 17.8 months. Ten patients have lived more than 2 years. Six of these patients have undergone total thoracic esophagectomy after the induction chemotherapy. Determination of the ultimate benefits of combined modality therapy may require prospective randomized trials isolating the major treatment components but our data suggest that chemotherapy contributes to improved results in this disease and that drug therapy is emerging as an integral component of combined therapy.

show abstract

“…Kelsen et al [40] were the first who reported on results with preoperative chemotherapy in patients with loco-regional esophageal carcinomas. They observed objective responses in 63% of 54 patients after cisplatin/vindesine/bleomycin chemotherapy.…”

Section: Preoperative Chemotherapy -Phase II Trialsmentioning

confidence: 99%

Chemotherapy of Esophageal Carcinoma

Ståhl¹

1999

Oncol Res Treat

View full text Add to dashboard Cite

Even today about 90% of patients with esophageal carcinoma will die from their disease. Due to late diagnosis of the disease and early metastatic spread of the tumor, local treatment modalities are curative only for a minority of the patients. Chemotherapy has gained an increasing importance in the treatment of esophageal cancer over the last years. Cisplatin and 5-fluorouracil (5-FU) are most meaningful, but vindesine, bleomycin, etoposide, paclitaxel, and vinorelbine also showed efficacy at least in squamous-cell carcinomas. Only 5-FU and paclitaxel were also effective in adenocarcinomas. The combination of 2 to 4 drugs resulted in increased remission rates, although by randomized trials this could not be translated into improved survival times for patients with advanced disease. Cisplatin/5-FU combination can be regarded as the standard treatment. By now it can not be said whether in this combination a biochemical modulation of 5-FU may be useful. The preoperative chemotherapy proved to be safe in several phase II trials and resulted in tumor downstaging in about 50% of the patients. The current results of phase III studies in resectable tumors did not prove a significant influence of preoperative chemotherapy on long-term survival, although most of these trials are of limited value due to small patient numbers and short observation times at the time of publication. Therefore, appropriate patients with resectable tumors should be treated in randomized trials with a surgery-only control arm. Phase II studies seem to be particularly useful for investigating new drugs or drug combinations in patients with advanced esophageal carcinomas.

show abstract

Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma

Cited by 119 publications

References 19 publications

Preoperative chemotherapy for esophageal carcinoma with intramural metastasis

Preoperative chemotherapy for esophageal carcinoma with intramural metastasis

Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer

Chemotherapy of Esophageal Carcinoma

Contact Info

Product

Resources

About